Andrew Sharabi
Overview
Explore the profile of Andrew Sharabi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers
Saidian A, Dolendo I, Sharabi A, Stewart T, Rose B, McKay R, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612124
As the indications for the use of immunotherapy in genitourinary malignancies expand, its role in combination with standard or conventional therapies has become the subject of contemporary studies. Radiotherapy has...
2.
Deichaite I, Hopper A, Krockenberger L, Sears T, Sutton L, Ray X, et al.
J Transl Med
. 2022 Aug;
20(1):360.
PMID: 35962345
Background: Precision medicine incorporating genetic profiling is becoming a standard of care in medical oncology. However, in the field of radiation oncology there is limited use of genetic profiling and...
3.
Saddawi-Konefka R, OFarrell A, Faraji F, Clubb L, Allevato M, Jensen S, et al.
Nat Commun
. 2022 Jul;
13(1):4298.
PMID: 35879302
Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain limited. This raises the possibility that standard of care treatments delivered in concert may compromise the tumor response. To...
4.
Joshi S, Sharabi A
Pharmacol Ther
. 2022 Feb;
235:108114.
PMID: 35122833
Myeloid-derived suppressor cells (MDSCs) are immune cells of the myeloid lineage that progressively accumulate in tumors and play an important role in promoting tumor growth. MDSCs interact with other immune...
5.
Gilardi M, Saddawi-Konefka R, Wu V, Lopez-Ramirez M, Wang Z, Soto F, et al.
Mol Cancer Ther
. 2022 Jan;
21(4):616-624.
PMID: 35086958
Head and neck squamous cell carcinoma (HNSCC) ranks sixth in cancer incidence worldwide and has a 5-year survival rate of only 63%. Immunotherapies-principally immune checkpoint inhibitors (ICI), such as anti-PD-1...
6.
Yusufaly T, Zou J, Nelson T, Williamson C, Simon A, Singhal M, et al.
J Nucl Med
. 2021 Oct;
63(7):1087-1093.
PMID: 34711618
Radiomics has been applied to predict recurrence in several disease sites, but current approaches are typically restricted to analyzing tumor features, neglecting nontumor information in the rest of the body....
7.
Bojechko C, Hua P, Sumner W, Guram K, Atwood T, Sharabi A
J Med Radiat Sci
. 2021 Oct;
69(2):267-272.
PMID: 34704381
Background: During a course of radiation therapy, anatomical changes such as a decrease in tumour size or weight loss can trigger the need for repeating a computed tomography (CT) simulation...
8.
Ahn G, Bruggeman A, Qiao E, Moiseenko V, Ray X, Sharabi A, et al.
Ann Palliat Med
. 2021 Oct;
10(10):10360-10368.
PMID: 34670382
Background: Radiation therapy plays an important role for symptom palliation for intrathoracic malignancies ineligible for curative-intent therapy. Limited data exists regarding the role of stereotactic body radiation therapy (SBRT) versus...
9.
Saddawi-Konefka R, Simon A, Sumner W, Sharabi A, Mell L, Cohen E
Front Oncol
. 2021 Oct;
11:738626.
PMID: 34621678
Recent advancements in the development of immunotherapies have raised the hope for patients with locally-advanced HNSCC (LA-HNSCC) to achieve improved oncologic outcomes without the heavy burden of treatment-related morbidity. While...
10.
Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E, et al.
Nat Commun
. 2020 Oct;
11(1):4965.
PMID: 33009371
Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting the molecular findings and accessing drugs/clinical trials is challenging. Furthermore, many tumors show resistance to monotherapies. To implement a precision...